NXC-201 vs. standard therapy for newly diagnosed AL amyloidosis
Part of Hormones & metabolism clinical trials.
This trial tests a new treatment called NXC-201 against a common combination therapy (daratumumab with CyBorD) for people newly diagnosed with AL amyloidosis who have not received treatment before. The goal is to see if NXC-201 works better at controlling the disease and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with AL amyloidosis and have not had any prior treatment for it.
- At least one of your organs (like heart, kidneys, or liver) is affected by the amyloidosis.
- Your disease can be measured with specific tests (your doctor will check this).
- You are in reasonably good health for your age (able to do daily activities with some help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
This trial tests a new investigational drug (etentamig) against a standard combination of four medicines to see which better controls the disease and its symptoms. It is for adults newly diagnosed with AL amyloidosis who have not yet been treated.
This trial tests a new drug combination for people with a specific type of AL amyloidosis (light chain amyloidosis) that has a genetic marker called t(11;14). The treatment includes Sonrotoclax (a targeted therapy) plus steroids, and possibly another drug called daratumumab, to see if it can help control the disease.
This trial tests a type of immunotherapy called CAR-T cells for people newly diagnosed with severe AL amyloidosis, a disease where abnormal proteins damage organs, especially the heart. It aims to see if this treatment can help control the disease.
This study tests whether a new antibody drug called elranatamab can help treat newly diagnosed AL amyloidosis (a disease where abnormal proteins build up in organs). If you haven't had treatment yet and have confirmed AL amyloidosis, this trial may offer access to an experimental therapy.
Hear when a new Light Chain (AL) Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.